Lexicon Pharma (LXRX) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.44 +1.41%
Revenue Growth %: -79.9%
Financial Fact:
Collaborative research: 27.69M
Today's EPS Names:
LTBR, AES, SYRS, More
Revenue Growth %: -79.9%
Financial Fact:
Collaborative research: 27.69M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.75 million versus the consensus estimate of $2.92 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Offerpad Solutions Inc. (OPAD) Misses Q3 EPS by 72c
- Parametric Sound (PAMT) Misses Q3 EPS by 31c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
